Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This study was not conducted in the United States. The purpose of this study was to assess
the safety and effectiveness of two doses of vildagliptin, an unapproved drug, in lowering
overall blood glucose levels in people with type 2 diabetes who had not previously been
treated with drug therapy to lower their blood sugar and whose blood sugar levels were in a
specified range.